Troponin, where do we go from here?

There remain some questions concerning the specifity of the troponins, especially cardiac troponin T. Nonetheless, they represent a substantial advance in both specificity for cardiac injury and improved sensitivity. Thus, it is likely that these markers will lead to the definition of new clinical syndromes by unmasking false positive elevations in MBCK and: by identifying elevations indicitave of cardiac abnormalities that could not be detected by any other means. The development of new more sensitive assays should further improve our understanding of disease processes that involve the heart by allowing for more subtle abnormalities to be detected.